Kyverna Therapeutics, Inc. (KYTX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
KYTX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Kyverna Therapeutics, Inc. (KYTX) trades at a price-to-earnings ratio of -2.8x, with a stock price of $9.30 and trailing twelve-month earnings per share of $-3.71.
Compared to the Healthcare sector median P/E of 22.3x, KYTX trades at a 113% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, KYTX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KYTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
See KYTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KYTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KYTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKYTX — Frequently Asked Questions
Quick answers to the most common questions about buying KYTX stock.
Is KYTX stock overvalued or undervalued?
KYTX current P/E: -2.8x. 5-year average P/E: N/A. Percentile: N/A.
How does KYTX's valuation compare to peers?
Kyverna Therapeutics, Inc. P/E of -2.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is KYTX's PEG ratio?
KYTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.